Gastric cancer biomarker analysis in patients treated with different adjuvant chemotherapy regimens within SAMIT, a phase III randomized controlled trial

Autor:	Oshima, Takashi, Tsuburaya, Akira, Yoshida, Kazuhiro, Yoshikawa, Takaki, Miyagi, Yohei, Rino, Yasushi, Masuda, Munetaka, Guan, Jia, Tan, Patrick, Grabsch, Heike I, Sakamoto, Junichi, Tanaka, Shiro
Přispěvatelé:	Pathologie, RS: GROW - R2 - Basic and Translational Cancer Biology
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	PROTEIN-TAU EXPRESSION CELL LUNG-CANCER PACLITAXEL Disease-Free Survival Paclitaxel/therapeutic use Local/drug therapy Chemotherapy Adjuvant/adverse effects MITOTIC CHECKPOINT Stomach Neoplasms Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor Chemotherapy Humans BREAST-CANCER Adjuvant/adverse effects Multidisciplinary Antineoplastic Combined Chemotherapy Protocols/adverse effects Pyrimidines/therapeutic use S-1 OPEN-LABEL Neoplasm Recurrence Local/drug therapy Pyrimidines Neoplasm Recurrence Chemotherapy Adjuvant Tumor/genetics SURVIVAL RNA Stomach Neoplasms/drug therapy Biomarkers Tumor/genetics Neoplasm Recurrence Local SENSITIVITY Biomarkers
Zdroj:	Scientific Reports, 12(1):8509. Nature Publishing Group
ISSN:	2045-2322
DOI:	10.1038/s41598-022-12439-3
Popis:	Biomarkers for selecting gastric cancer (GC) patients likely to benefit from sequential paclitaxel treatment followed by fluorinated-pyrimidine-based adjuvant chemotherapy (sequential paclitaxel) were investigated using tissue samples of patients recruited into SAMIT, a phase III randomized controlled trial. Total RNA was extracted from 556 GC resection samples. The expression of 105 genes was quantified using real-time PCR. Genes predicting the benefit of sequential paclitaxel on overall survival, disease-free survival, and cumulative incidence of relapse were identified based on the ranking of p-values associated with the interaction between the biomarker and sequential paclitaxel or monotherapy groups. Low VSNL1 and CD44 expression predicted the benefit of sequential paclitaxel treatment for all three endpoints. Patients with combined low expression of both genes benefitted most from sequential paclitaxel therapy (hazard ratio = 0.48 [95% confidence interval, 0.30–0.78]; p VSNL1 and CD44 RNA expression levels as biomarkers for selecting GC patients that are likely to benefit from sequential paclitaxel treatment followed by fluorinated-pyrimidine-based adjuvant chemotherapy. Our findings may facilitate clinical trials on biomarker-oriented postoperative adjuvant chemotherapy for patients with locally advanced GC.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38d9b4e8b52dc1b544df3051ce391d73 https://doi.org/10.1038/s41598-022-12439-3 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.